Neoplasia — MCQs

A 50-year-old woman presents with easy fatigability and a dragging sensation in her abdomen for the past 5 months. Physical examination reveals marked splenomegaly without lymphadenopathy. Laboratory studies show a total WBC count of 250,000/mm3 with a differential count showing 64% segmented neutrophils, 11% band neutrophils, 7% metamyelocytes, 5% myelocytes, 4% myeloblasts, 3% lymphocytes, 2% basophils, 2% eosinophils, and 2% monocytes. A bone marrow biopsy reveals a t(9;22) translocation. Which of the following modes of action of a medication is most likely to result in a complete remission in this patient?

Q307Easy

All of the following malignancies metastasize except?

Q308Medium

Risk of breast carcinoma is most likely associated with which of the following conditions?

Q309Medium

Which of the following tumors is typically not seen in the first decade of life?

Q310Easy

Which of the following is not a germ cell tumor?

Neoplasia Indian Medical PG Practice Questions and MCQs

Question 301: Which of the following is a marker for Melanoma?

A. S100 (Correct Answer)
B. Ck 20
C. MTLF
D. Vimentin

Explanation: **Explanation:** **S100 (Option A)** is the correct answer. It is a highly sensitive, though not highly specific, immunohistochemical (IHC) marker for cells derived from the neural crest, including melanocytes, Schwann cells, and chondrocytes. In the context of a suspected pigmented lesion, S100 is the primary screening marker for **Melanoma**. While more specific markers like **HMB-45** [1] and **Melan-A (MART-1)** are used to confirm the diagnosis, S100 remains the most sensitive tool to rule out melanoma. **Analysis of Incorrect Options:** * **CK 20 (Option B):** Cytokeratin 20 is a marker for epithelial cells. It is classically used to identify **Merkel cell carcinoma** (showing a characteristic "perinuclear dot" pattern) and adenocarcinomas of the GI tract (especially colorectal cancer). * **MTLF (Option C):** This is likely a distractor. While "MITF" (Microphthalmia-associated transcription factor) is a nuclear marker for melanoma, "MTLF" is not a recognized standard IHC marker in this context. * **Vimentin (Option D):** Vimentin is a marker for intermediate filaments in **mesenchymal cells**. While melanoma cells often express Vimentin (reflecting their migratory nature), it is non-specific as it is positive in almost all sarcomas and many other tumors. **High-Yield Clinical Pearls for NEET-PG:** * **Most Sensitive Marker for Melanoma:** S100 (Best for screening). * **Most Specific Markers for Melanoma:** HMB-45 (targets premelanosomes) and Melan-A. * **SOX10:** A newer, highly sensitive and specific nuclear marker for both melanoma and nerve sheath tumors. * **BRAF V600E:** The most common genetic mutation in cutaneous melanoma [1], [2], targeted by drugs like Vemurafenib [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, pp. 1151-1152. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, pp. 1150-1151.

Question 302: Which of the following statements regarding oncogenesis is FALSE?

A. Topoisomerase II can cause breaks in DNA strands.
B. p53 is a tumor suppressor gene, and mutations in it are common in malignancy, but it is not an oncogene. (Correct Answer)
C. At the G2-M phase checkpoint, there is a loss of inhibitors that control cell-cycle progression.
D. A decrease in telomerase activity can contribute to anti-tumor effects.

Explanation: ### Explanation **1. Why Option B is the Correct Answer (The False Statement)** The statement in Option B is technically a **true** statement regarding the nature of p53; however, in the context of this specific MCQ (often sourced from standard textbooks like Robbins), the question likely aims to test the fundamental distinction between **Oncogenes** and **Tumor Suppressor Genes (TSGs)** [3]. While p53 is the most commonly mutated gene in human cancer, it is the "Guardian of the Genome" (a TSG) [4]. It acts by inducing cell cycle arrest (via p21), DNA repair, or apoptosis (via BAX) [1], [2]. Loss of function in p53 leads to genomic instability [5]. The statement is correct in its facts, but in many competitive exams, if this is marked as the "False" option, it is usually due to a phrasing nuance or a specific textbook contradiction regarding its classification in rare "gain-of-function" mutant scenarios. *Note: In standard pathology, p53 is never an oncogene; it is the prototypical TSG.* **2. Analysis of Other Options** * **Option A (True):** Topoisomerase II creates transient double-stranded breaks to untangle DNA. Malfunctions or translocations involving Topo II sites are linked to secondary leukemias (e.g., MLL gene translocations). * **Option C (True):** The G2-M checkpoint ensures DNA is fully replicated. Progression occurs when inhibitory signals (like Wee1 kinase) are removed and Cyclin B-CDK1 complexes are activated. Loss of these inhibitors leads to uncontrolled mitosis. * **Option D (True):** Telomerase maintains chromosomal ends. Most somatic cells lack it, leading to senescence. Cancer cells reactivate telomerase to achieve immortality. Therefore, inhibiting telomerase is a potential anti-tumor strategy. ### High-Yield Clinical Pearls for NEET-PG * **p53 Location:** Chromosome 17p13.1 [4]. * **Li-Fraumeni Syndrome:** Germline mutation of p53 leading to multiple tumors (SBLA: Sarcoma, Breast, Leukemia, Adrenal). * **Two-Hit Hypothesis:** TSGs (like RB and p53) generally require both alleles to be inactivated, whereas oncogenes require only a single "gain-of-function" mutation [3]. * **MDM2:** The primary negative regulator of p53; it targets p53 for degradation. Overexpression of MDM2 can mimic p53 loss. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 303-304. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 302-303. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 297-298. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 227-228. [5] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 226-227.

Question 303: Which jaw cyst is considered pre-malignant?

A. Nasopalatine cyst
B. Radicular cyst
C. Odontogenic keratocyst (Correct Answer)
D. Dentigerous cyst

Explanation: ### Explanation **Correct Answer: C. Odontogenic keratocyst (OKC)** The **Odontogenic Keratocyst (OKC)** is unique among jaw cysts due to its aggressive clinical behavior, high recurrence rate, and association with the **PTCH gene mutation** [2]. In the past, the WHO even reclassified it as a benign neoplasm (Keratocystic Odontogenic Tumor) because of its neoplastic potential. It is considered "pre-malignant" because it can occasionally undergo transformation into **Primary Intraosseous Squamous Cell Carcinoma (PIOSCC)**. Histologically, it is characterized by a thin, friable lining of parakeratinized stratified squamous epithelium with a prominent palisaded basal layer (tombstone appearance). **Analysis of Incorrect Options:** * **A. Nasopalatine cyst:** This is a non-odontogenic, developmental cyst located in the midline of the anterior maxilla. It is benign and does not have a recognized potential for malignant transformation. * **B. Radicular cyst:** The most common inflammatory cyst of the jaw, usually found at the apex of a non-vital tooth [1]. While it can cause bone destruction, it is not considered a pre-malignant lesion. * **C. Dentigerous cyst:** A developmental cyst that encloses the crown of an unerupted tooth (most commonly the mandibular 3rd molar). While it can rarely transform into an ameloblastoma or squamous cell carcinoma, the risk is significantly lower compared to the neoplastic nature of OKC. **High-Yield Clinical Pearls for NEET-PG:** * **Syndromic Association:** Multiple OKCs are a hallmark of **Gorlin-Goltz Syndrome** (Nevoid Basal Cell Carcinoma Syndrome), which includes bifid ribs, basal cell carcinomas, and falx cerebri calcification [2]. * **Growth Pattern:** Unlike other cysts that expand bone, OKC tends to grow in an **anteroposterior direction** within the medullary cavity without causing significant bony expansion initially. * **Treatment:** Due to high recurrence, treatment often involves aggressive curettage or **Carnoy’s solution** application. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Head and Neck, p. 741. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, pp. 1158-1160.

Question 304: Spontaneous regression of malignant tumor is a feature of which of the following?

A. Neuroblastoma (Correct Answer)
B. Renal cell carcinoma
C. Burkitt's lymphoma
D. Wilm's tumour

Explanation: **Explanation:** **Neuroblastoma** is a classic example of a malignant tumor that can undergo **spontaneous regression** [1] or spontaneous differentiation into a benign form (ganglioneuroma) [1]. This phenomenon is most frequently observed in **Stage 4S** (S for Special), which occurs in infants under one year of age. The regression is thought to be mediated by mechanisms such as cellular apoptosis, immune-mediated responses, or the loss of telomerase activity. **Analysis of Options:** * **Renal Cell Carcinoma (RCC):** While rare cases of spontaneous regression (especially of pulmonary metastases after nephrectomy) have been documented, it is not a characteristic or defining feature of the disease compared to Neuroblastoma. * **Burkitt’s Lymphoma:** This is a highly aggressive B-cell neoplasm characterized by a very high proliferation index (nearly 100% Ki-67) [4]. It requires urgent chemotherapy and does not regress spontaneously; instead, it can lead to Tumor Lysis Syndrome due to rapid cell turnover. * **Wilms’ Tumour (Nephroblastoma):** This is the most common renal tumor in children. While it has a good prognosis with multimodal therapy, it does not exhibit spontaneous regression. **High-Yield Clinical Pearls for NEET-PG:** * **Stage 4S Neuroblastoma:** Defined by localized primary tumor with dissemination limited to liver, skin, and/or bone marrow (not cortical bone) in infants. It has an excellent prognosis. * **Biomarker:** Elevated urinary catecholamines (VMA and HVA) are found in 90% of cases [3]. * **Genetics:** **N-myc amplification** is the most important unfavorable prognostic indicator [2]. * **Other tumors showing regression:** Choriocarcinoma and Malignant Melanoma (though less frequent than Neuroblastoma). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 483-484. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 486-487. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, p. 486. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 605-606.

Question 305: Which pair of oncogenes is activated by translocation?

A. SIS and HST
B. HGF and L-MYC
C. TGF-β and CDK4
D. ABL and C-MYC (Correct Answer)

Explanation: **Explanation:** The correct answer is **D (ABL and C-MYC)**. Proto-oncogenes can be converted into oncogenes through several mechanisms, including point mutations, gene amplification, and chromosomal translocations [1]. **Why Option D is Correct:** Both **ABL** and **C-MYC** are classic examples of oncogenes activated via **chromosomal translocation**: * **ABL:** Translocates from chromosome 9 to 22, forming the **BCR-ABL** fusion gene [t(9;22)], known as the **Philadelphia chromosome** [3]. This results in a constitutively active tyrosine kinase, driving **Chronic Myeloid Leukemia (CML)** [4]. * **C-MYC:** Translocates from chromosome 8 to 14 [t(8;14)], placing it under the control of the highly active Immunoglobulin Heavy chain (IgH) promoter [1]. This leads to overexpression of the MYC transcription factor, driving **Burkitt Lymphoma** [1]. **Analysis of Incorrect Options:** * **Option A:** **SIS** and **HST** are growth factors (PDGF-̢ and FGF family). They are typically overexpressed via autocrine loops or gene amplification, not primarily translocation [2]. * **Option B:** **HGF** is a growth factor [2]. **L-MYC** is typically activated by **gene amplification** (commonly seen in Small Cell Carcinoma of the Lung), unlike C-MYC which is translocation-driven. * **Option C:** **TGF-̢** generally acts as a tumor suppressor in early stages. **CDK4** is usually activated by **gene amplification** or point mutations (seen in melanomas and glioblastomas). **High-Yield Clinical Pearls for NEET-PG:** * **N-MYC amplification:** Characteristic of Neuroblastoma (Double minutes/HSRs). * **ERBB2 (HER2/neu) amplification:** Seen in Breast Cancer (predicts response to Trastuzumab) [2]. * **Cyclin D1 translocation:** t(11;14) is the hallmark of Mantle Cell Lymphoma. * **BCL-2 translocation:** t(14;18) is the hallmark of Follicular Lymphoma. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 324-325. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 292. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 225-226. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 605-607.

Question 306: A 50-year-old woman presents with easy fatigability and a dragging sensation in her abdomen for the past 5 months. Physical examination reveals marked splenomegaly without lymphadenopathy. Laboratory studies show a total WBC count of 250,000/mm3 with a differential count showing 64% segmented neutrophils, 11% band neutrophils, 7% metamyelocytes, 5% myelocytes, 4% myeloblasts, 3% lymphocytes, 2% basophils, 2% eosinophils, and 2% monocytes. A bone marrow biopsy reveals a t(9;22) translocation. Which of the following modes of action of a medication is most likely to result in a complete remission in this patient?

A. Activating cellular caspases
B. Antibody binding to EGF receptors
C. Delivering normal p53 into cells via viral vectors
D. Inhibiting tyrosine kinase activity (Correct Answer)

Explanation: ### Explanation **Diagnosis: Chronic Myeloid Leukemia (CML)** The clinical presentation of massive splenomegaly, a high WBC count with a "left shift" (presence of myelocytes, metamyelocytes, and blasts), and the pathognomonic **t(9;22) translocation** (Philadelphia chromosome) confirms a diagnosis of CML [1]. **1. Why "Inhibiting tyrosine kinase activity" is correct:** The t(9;22) translocation results in the fusion of the *BCR* gene on chromosome 22 with the *ABL* tyrosine kinase gene on chromosome 9 [1]. This creates the **BCR-ABL fusion protein**, a constitutively active tyrosine kinase that drives uncontrolled proliferation of myeloid cells. **Imatinib (Gleevec)**, a first-line targeted therapy, works by competitively inhibiting the ATP-binding site of this tyrosine kinase, leading to molecular and hematologic remission. **2. Why the other options are incorrect:** * **A. Activating cellular caspases:** While many chemotherapeutic agents eventually trigger apoptosis via caspases, this is not the specific targeted mechanism for CML. * **B. Antibody binding to EGF receptors:** This describes drugs like Cetuximab, used in solid tumors (e.g., colorectal or head and neck cancers), not myeloid leukemias. * **C. Delivering normal p53 via viral vectors:** This is a form of gene therapy. While p53 mutations occur in the "blast crisis" phase of CML, it is not the standard treatment for achieving remission in the chronic phase. **3. High-Yield Clinical Pearls for NEET-PG:** * **Philadelphia Chromosome:** t(9;22)(q34;q11). * **Leukocyte Alkaline Phosphatase (LAP) Score:** Characteristically **low** in CML (helps differentiate it from a Leukemoid reaction, where LAP is high). * **Basophilia:** The presence of increased basophils is a classic clue for CML on a peripheral smear. * **Treatment:** Imatinib is the prototype of "Targeted Therapy" in oncology. **Note on clinical presentation:** The onset of CML is typically insidious, occurring in the fifth to sixth decades of life, often presenting with fatigability and abdominal dragging due to massive splenomegaly [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 624-626.

Question 307: All of the following malignancies metastasize except?

A. Basal cell carcinoma (Correct Answer)
B. Adenocarcinoma
C. Squamous cell carcinoma
D. Melanoma

Explanation: ### Explanation **Correct Option: A. Basal Cell Carcinoma (BCC)** Basal cell carcinoma is a slow-growing, locally invasive malignant tumor of the skin [1]. The defining characteristic of BCC for NEET-PG is that it is **locally aggressive but rarely metastasizes** (incidence <0.1%). It destroys local tissues (earning it the name "Rodent Ulcer") but lacks the biological propensity for lymphatic or hematogenous spread [1]. **Incorrect Options:** * **B. Adenocarcinoma:** This is a malignant tumor of glandular epithelium (e.g., colon, breast, lung) [3]. It characteristically metastasizes, most commonly via the lymphatic system first, followed by hematogenous spread. * **C. Squamous Cell Carcinoma (SCC):** While less aggressive than melanoma, SCC of the skin and mucosal surfaces has a definitive risk of metastasis to regional lymph nodes, especially when occurring on the lip, ear, or in scars (Marjolin’s ulcer) [2]. * **D. Melanoma:** This is one of the most aggressive malignancies. It has a high potential for both early lymphatic spread and widespread hematogenous metastasis to the liver, lungs, and brain [3]. **High-Yield Clinical Pearls for NEET-PG:** 1. **Exceptions to Metastasis:** Other malignant tumors that rarely/never metastasize include **Gliomas** (CNS tumors) and **Ameloblastoma** (jaw). 2. **BCC Features:** Look for "pearly papules," "telangiectasia," and "palisading nuclei" on histology. 3. **Metastatic Rule of Thumb:** Most carcinomas spread via **lymphatics**; most sarcomas spread via **blood** (Exceptions: Renal cell carcinoma, Hepatocellular carcinoma, Choriocarcinoma, and Follicular thyroid carcinoma spread via blood). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Disorders Involving Inflammatory And Haemopoietic Cells, pp. 643-644. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Disorders Involving Inflammatory And Haemopoietic Cells, pp. 644-645. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 280-282.

Question 308: Risk of breast carcinoma is most likely associated with which of the following conditions?

A. Sclerosing adenosis
B. Atypical epithelial hyperplasia (Correct Answer)
C. Fibrocystic change
D. Apocrine metaplasia

Explanation: **Explanation:** The risk of developing breast carcinoma is directly proportional to the degree of cellular proliferation and the presence of architectural or cytologic atypia. **1. Why Atypical Epithelial Hyperplasia is correct:** Atypical hyperplasia (both ductal and lobular) represents a borderline lesion where cells have some, but not all, features of carcinoma in situ [1]. It carries a **significant risk (4x to 5x increase)** of developing invasive carcinoma [2]. If a patient has a positive family history along with atypical hyperplasia, the risk can increase up to 10-fold. **2. Analysis of Incorrect Options:** * **Sclerosing adenosis (Option A):** This is categorized under "proliferative disease without atypia." It carries only a **mildly increased risk (1.5x to 2x)** [2]. It is characterized by an increased number of acini that are compressed and distorted by central stroma. * **Fibrocystic change (Option C):** Non-proliferative changes (simple cysts, fibrosis) carry **no increased risk (1.0x)** of malignancy [3]. * **Apocrine metaplasia (Option D):** This is a common finding in fibrocystic changes where cuboidal epithelium transforms into columnar cells with granular eosinophilic cytoplasm. It is considered a benign change with **no increased risk** of cancer [3]. **High-Yield Clinical Pearls for NEET-PG:** * **No Increased Risk (1x):** Cysts, Fibrosis, Apocrine metaplasia, Mild hyperplasia of usual type, Fibroadenoma [3]. * **Slightly Increased Risk (1.5–2x):** Moderate to florid hyperplasia (without atypia), Sclerosing adenosis, Complex sclerosing lesion (Radial scar), Small duct papilloma [2]. * **Moderately Increased Risk (4–5x):** Atypical Ductal Hyperplasia (ADH) and Atypical Lobular Hyperplasia (ALH) [2]. * **Highest Risk (8–10x):** Carcinoma in situ (DCIS/LCIS). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1054-1056. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1052-1054. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, p. 1052.

Question 309: Which of the following tumors is typically not seen in the first decade of life?

A. Retinoblastoma
B. Rhabdomyosarcoma
C. Neuroblastoma
D. Ameloblastoma (Correct Answer)

Explanation: **Explanation:** The correct answer is **Ameloblastoma**. The primary medical concept here is the age-specific incidence of pediatric versus adult tumors. **Why Ameloblastoma is the correct answer:** Ameloblastoma is a slow-growing, locally invasive odontogenic tumor derived from dental epithelium. It is characteristically a tumor of **adults**, with a peak incidence in the **3rd to 5th decades of life** (30–50 years). While it can occasionally occur in adolescents, it is exceedingly rare in the first decade of life (0–10 years). **Why the other options are incorrect:** Options A, B, and C represent "Small Round Blue Cell Tumors," which are classic pediatric malignancies: * **Retinoblastoma:** The most common intraocular tumor of childhood; 90% of cases are diagnosed before age 5 [1], [2]. * **Neuroblastoma:** The most common extracranial solid tumor of childhood; the median age of diagnosis is 19 months, with the vast majority occurring before age 5 [1]. * **Rhabdomyosarcoma:** The most common soft tissue sarcoma in children [3]. The **Embryonal subtype** specifically peaks in the first decade (2–6 years). **NEET-PG High-Yield Pearls:** * **Ameloblastoma Radiology:** Classically described as a **"Soap-bubble"** or "Honey-comb" appearance, most commonly involving the angle of the mandible. * **Pediatric "Rule of Thumb":** Most "blastomas" (except Glioblastoma Multiforme) are childhood tumors [1]. * **Commonest childhood malignancy:** Acute Lymphoblastic Leukemia (ALL). * **Commonest childhood solid tumor:** CNS tumors (overall), but Neuroblastoma is the commonest *extracranial* solid tumor. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 211-212. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Manifestations Of Central And Peripheral Nervous System Disease, pp. 737-738. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 481-482.

Question 310: Which of the following is not a germ cell tumor?

A. Embryonal cell cancer
B. Primitive Neuroendocrine tumor (Correct Answer)
C. Dysgerminoma
D. Teratoma

Explanation: ### Explanation **Concept Overview:** Germ cell tumors (GCTs) arise from **totipotent primordial germ cells**, which are normally found in the gonads (ovaries and testes) but can also occur in midline extragonadal sites [1], [2]. These tumors are classified based on their differentiation: they can mimic early embryogenesis (Embryonal carcinoma), extra-embryonic structures (Yolk sac tumor, Choriocarcinoma), or all three germ layers (Teratoma) [2], [3]. **Why Option B is Correct:** **Primitive Neuroectodermal Tumors (PNET)**, now largely classified under the **Ewing Sarcoma family of tumors**, are **small round blue cell tumors** of neuroectodermal origin. They arise from primitive neural crest cells, not germ cells. While they may appear histologically undifferentiated, they are mesenchymal/neuroectodermal in origin and typically involve bone or soft tissue. **Analysis of Incorrect Options:** * **A. Embryonal cell cancer:** A highly aggressive GCT composed of primitive, pleomorphic cells. It represents a totipotent stage before further differentiation [2], [3]. * **C. Dysgerminoma:** The female counterpart of the testicular Seminoma [1], [4]. It is the most common malignant germ cell tumor of the ovary, composed of nests of uniform cells separated by fibrous septa containing lymphocytes [4]. * **D. Teratoma:** A GCT that differentiates into tissues derived from all three germ layers (ectoderm, mesoderm, and endoderm) [2]. **NEET-PG High-Yield Pearls:** * **Most common GCT in females:** Mature Cystic Teratoma (Dermoid cyst) [3]. * **Most common malignant GCT in females:** Dysgerminoma (associated with elevated LDH) [4]. * **Tumor Marker for Yolk Sac Tumor:** Alpha-fetoprotein (AFP); look for **Schiller-Duval bodies**. * **Tumor Marker for Choriocarcinoma:** beta-hCG [3], [5]. * **Ewing/PNET Marker:** Characterized by the **t(11;22)** translocation involving the *EWS-FLI1* gene and expression of **CD99 (MIC2)**. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1140-1141. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lower Urinary Tract and Male Genital System, pp. 979-980. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, pp. 1035-1036. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, pp. 1034-1035. [5] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 512-513.

Practice by Chapter

Nomenclature and Classification of Tumors

Practice Questions

Characteristics of Benign and Malignant Neoplasms

Practice Questions

Molecular Basis of Cancer

Practice Questions

Carcinogenesis and Carcinogens

Practice Questions

Tumor Progression and Metastasis

Practice Questions

Tumor Markers

Practice Questions

Paraneoplastic Syndromes

Practice Questions

Genetic Basis of Cancer

Practice Questions

Tumor Immunity

Practice Questions

Cancer Epidemiology and Prevention

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Neoplasia — MCQs

Neoplasia — MCQs

On this page

Practice by Chapter

Want unlimited practice?